Linked Life Data

8160137

Source:http://linkedlifedata.com/resource/pubmed/id/8160137

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1994-5-16
pubmed:abstractText
The paper reports the results of a randomized clinicoimmunological trial of domestic recombinant alpha 2-interferon (reaferon) in 30 patients with protracted viral hepatitis (27 subjects had viral hepatitis B and 3 patients HBV + HDV-coinfection). The reaferon treatment started on the disease week 7-8 and lasted for 2 months (1 x 10(6) IU, once a week, i.m.). VHB patients benefited from reaferon treatment as evident from improved clinical and laboratory indices, cases of complete cure and the agent elimination. In a protracted course of HBV + HDV coinfection reaferon in the above doses failed to produce any effect.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0040-3660
pubmed:author
pubmed:issnType
Print
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-4
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
[The use of reaferon in treating patients with protracted viral hepatitis].
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, English Abstract, Randomized Controlled Trial